Novel compounds

Compounds of formula (I): wherein: R1 represents substituted or unsubstituted heteroaryl; Y represents -(CRnaRnb)n-; Rna and Rnb are each independently hydrogen or C1-6alkyl; n is an integer from 0 to 5; R2 represents unsubstituted or substituted aryl or unsubstituted or substituted heteroaryl; R3 a...

Full description

Saved in:
Bibliographic Details
Main Authors DUNCAN BRUCE JUDD, GORE, PAUL MARTIN, SIMON TEANBY HODGSON, GAIL MILLS, ELDRED, COLIN DAVID, HARRISON, LEE ANDREW, ANCLIFF, RACHAEL ANN, COOK, CAROLINE MARY, XIAO QING LEWELL, MARK WILKINSON, STEPHEN SWANSON, MARTIN ALISTAIR HAYES, GRAEME MICHAEL ROBERTSON, ANDREW JOHN WALKER, SUZANNE ELAINE KEELING
Format Patent
LanguageChinese
English
Published 01.01.2004
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Compounds of formula (I): wherein: R1 represents substituted or unsubstituted heteroaryl; Y represents -(CRnaRnb)n-; Rna and Rnb are each independently hydrogen or C1-6alkyl; n is an integer from 0 to 5; R2 represents unsubstituted or substituted aryl or unsubstituted or substituted heteroaryl; R3 and R4 each independently represent hydrogen or C1-6alkyl; R7 represents hydrogen or C1-6alkyl; R8 represents hydrogen or C1-6alkyl; and salts and solvates thereof; are CCR3 antagonists and are thus indicated to be useful in therapy.
Bibliography:Application Number: TW200392106766